Lab21 Plans to Commercialize CES-1 Gene Variants as PGx Test Kits | GenomeWeb

Originally published Aug. 27.

UK-based personalized medicine firm Lab21 will be offering analysis of the CES-1 gene, which has been shown in studies to influence the metabolism of a number of commonly prescribed drugs in people who harbor mutations in this gene.

Lab21 this week said that it has taken a global license from the Medical University of South Carolina's Foundation for Research Development allowing for the detection and analysis of genetic variants of the human carboxylesterase-1 gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.